Sorriso Pharmaceuticals, Inc. announced that it has received $31 million in funding from New Enterprise Associates, Inc., Arix Bioscience plc and other investors

On December 22, 2021, Sorriso Pharmaceuticals, Inc. closed the transaction. The company has raised $31,00,000 in the round of funding co-led by new investors New Enterprise Associates, Inc, and Arix Bioscience plc for 26% stake on fully diluted basis for $13,000,000. The transaction involved participation form total 11 investors.

The company has raised $21,293,856 by issuing securities pursuant to regulation D. As part of the transaction Mark Chin from Arix Bioscience plc and Ed Mathers from New Enterprise Associates, Inc had joined the company's board.